Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of tildrakizumab in axial spondyloarthritis
2016-003936-19Phase 2Terminated
- Sponsor
- Sun Pharma
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) comparing Tildrakizumab with Placebo (2 arms). Primary endpoint: ASAS40 response at Week 24. Started Jan 2017; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2016-003936-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003936-19.